The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands ...
An earlier FTC report published in July 2024 argued that the six largest PBMs were effectively running a monopoly that gave them enormous power over the price of medicines and allowed them to ...
Outrage against PBMs was on full display when 400 pharmacy professionals in Kansas shuttered their businesses and petitioned ...
Finally, blaming the pharmaceutical industry for high drug costs has historically been PBMs’ go-to defense. In a rebuttal to the FTC report issued in the summer, the PCMA criticized the ...
The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...
Below, we summarize the major findings from the Second Report, discuss potential next steps by the FTC (and others), and offer some key takeaways. In the complex world of health insurance ...
In this Special Edition of the PBM Policy and Legislative Update, the Mintz Health team partnered with our Antitrust colleagues to analyze the FTC’s Second Report. Please see full publication ...
CVS Health reported $1.6 billion in profit for the fourth quarter, down from a $2 billion haul a year ago, according to its ...
The Federal Trade Commission published a second interim staff report this week on the prescription drug middleman industry, which focuses on pharmacy benefit managers’ (PBMs) influence over ...
The FTC’s report details how these PBMs strategically steered patients toward their affiliated pharmacies, where prescription costs often exceeded those at independent pharmacies by more than ...
In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical specialty generic drugs, marking up the prices of drugs by hundreds and ...
However, a report last year from The House of Representatives and another more recently from the Federal Trade Commission (FTC) argue that PBMs have used this position to drive up drug costs for ...